Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

DNA interaction could unlock targeted therapeuticsDid you know that every cell in our body has the same DNA inside ...

Nucleosomes are barriers to RNA Polymerase II (Pol II) transcribing along gene bodies in eukaryotes. We found that a fragile “tailless nucleosome” could be generated to resolve the Pol II pausing ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Itaconate, an endogenous mitochondrial metabolite produced by the enzyme aconitate decarboxylase 1 (ACOD1), has emerged as a central regulator of ...

Department of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, United States ...

UCP's Grant Program invests in research that translates scientific insights into practical improvements in early ...

Phrasing is "anything but objective," former Journal of the American Medical Association deputy editor says. Harvard-led ...

In a striking real-world experiment, flu patients spent days indoors with healthy volunteers, but the virus never spread.

PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage ...

Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into ...